Table 3 Multivariable analyses of overall survival and progression-free survival in patients with available pre-treatment C-reactive protein-to-albumin ratio data.

From: High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma

 

OS

PFS

HR

(95% CI)

p

HR

(95% CI)

p

Age > 60 years

2.91

(1.05–8.07)

0.040

1.90

(0.93–3.89)

0.080

Stage (III, IV)

2.15

(0.54–8.57)

0.278

2.52

(1.00–6.36)

0.050

LDH > UNL

1.77

(0.34–9.19)

0.499

1.16

(0.44–3.05)

0.769

ECOG PS > 1

1.96

(0.77–4.97)

0.158

1.81

(0.85–3.84)

0.124

EN > 1

1.26

(0.48–3.35)

0.637

0.96

(0.46–1.98)

0.908

CAR > 0.158

6.02

(1.19–30.38)

0.030

3.62

(1.40–9.36)

0.008

IPI ≥ 3

8.97

(1.93–41.63)

0.005

3.17

(1.43–7.00)

0.004

CAR > 0.158

4.35

(0.94–20.15)

0.060

3.35

(1.36–8.20)

0.008

  1. OS overall survival, PFS progression-free survival, HR hazard ratio, CI confidence interval, LDH lactate dehydrogenase, UNL upper normal limit, ECOG PS Eastern Cooperative Oncology Group performance status, EN extranodal, CAR C-reactive protein-to-albumin ratio, IPI international prognostic index.
Back to article page